[go: up one dir, main page]

WO2013097965A1 - Arn bicaténaire contenant un triphosphate pour l'immunostimulation - Google Patents

Arn bicaténaire contenant un triphosphate pour l'immunostimulation Download PDF

Info

Publication number
WO2013097965A1
WO2013097965A1 PCT/EP2012/071641 EP2012071641W WO2013097965A1 WO 2013097965 A1 WO2013097965 A1 WO 2013097965A1 EP 2012071641 W EP2012071641 W EP 2012071641W WO 2013097965 A1 WO2013097965 A1 WO 2013097965A1
Authority
WO
WIPO (PCT)
Prior art keywords
ppp
ribonucleic acid
double
strand
stranded structure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2012/071641
Other languages
English (en)
Inventor
Jacques Rohayem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RiboxX GmbH
Original Assignee
RiboxX GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RiboxX GmbH filed Critical RiboxX GmbH
Publication of WO2013097965A1 publication Critical patent/WO2013097965A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Definitions

  • the present invention relates to immunostimulative double-stranded RNA of at least 45 base pairs or RNA having at least a double-stranded segment of at least 45 base pairs, respectively, wherein the RNA contains a free triphosphate group at the 5'-end of at least one strand.
  • RNA causes immunostimulation through the TLR-3 located in endosomes of dendritic and epithelial cells (see Kucnick et al. (2010) Current Medical Chemistry; Coffmann et al. (2010) Immunity).
  • WO 2008/017473 A2 teaches that single-stranded oligonucleotides bearing free uncapped 5' phosphate groups are recognised by RIG-I leading to induction of type I IFN, IL-18 and I L-1 ⁇ .
  • the technical problem underlying the present invention is to provide an improved system for immunostimulation using RNA molecules.
  • the present invention provides a ribonucleic acid comprising at least one segment of double-stranded structure of at least 45 bp, preferably of at least 48 bp, more preferably of at least 70 bp, particularly preferred of from 45, 46, 47 or 48 to 200 bp, wherein said at least one segment of double-stranded structure has a first and a second end each having at least 2 to 10 G/C bp within the last 4 to 20, respectively, bp calculated from the last bp of the respective end of the double-stranded structure, and wherein the ribonucleic acid comprises a free triphosphate group at the 5'-end of at least one strand of the ribonucleic acid.
  • a "free triphosphate group" in context of the present invention means that this triphosphate group is not modified and specifically does not contain or is not part of, respectively, a cap structure.
  • the free triphosphate-containing double-stranded ribonucleic acids of the present invention trigger both RIG-I (see. e.g. WO 2008/017473 A2) and TLR-3 pathways and exert a dose- dependent innate immune response as demonstrated herein.
  • RIG-I see. e.g. WO 2008/017473 A2
  • TLR-3 pathways exert a dose- dependent innate immune response as demonstrated herein.
  • triphosphate- containing dsRNAs according to the invention exert a substantially stronger
  • the triphosphate-containing ribonucleic acid of the present invention preferably has at least a segment of double-strand structure of a minimum of 45 bp wherein said double-stranded segment has increased thermodynamic stability on both ends (or end regions) of the dsRNA or dsRNA segment, respectively.
  • a ribonucleic acid comprising at least one segment of double- stranded structure of at least 45 bp, preferably of at least 48 bp, more preferably of at least 70 bp, particularly preferred of from 45, 46, 47 or 48 to 200 bp or even more bp, wherein said at least one segment of double-stranded structure has a first and a second end each having at least 2 to 10 (preferably consecutive) G/C bp within the last 4 to 20, respectively, bp calculated from the last bp of the respective end of the double-stranded structure.
  • the ribonucleic acid of the present invention displays a triggering of the TLR-3 pathway in combination with RIG-I stimulation leading to a sustained and powerful immunostimulation (innate immune response).
  • G/C bp within the last 6 to 20 bp at each end of the double-stranded ribonucleic acid or of the double-stranded segment of the ribonucleic acid, respectively, typically means that at least 50 % of the last 4 to 20 bp at each end of the double-stranded structure are G/C base pairs, preferably the G/C base pairs are
  • At least 2 G/C base pairs are present within the last 4 bp, at least 3 G/C base pairs are present within the last 6 bp, at least 4 G/C base pairs are present within the last 8 bp, or at least 5 G/C base pairs are present within the last 10 bp, and so on, at both ends of the double-stranded structure.
  • nucleotide sequence of the ribonucleic acid according to the invention between the G/C rich end regions as outlined above is in general not critical. However, it is preferred that the nucleotide sequence between the last 6 to 20 bp at each end is heteropolymeric.
  • the at least 3 to 10 terminal bp of each end of the double-stranded structure in the ribonucleic acid of the invention are G/C bp.
  • the ribonucleic acid or double-stranded segment of the nucleic acid of the present invention has a nucleotide sequence that can be represented by the following general formula (1 ): wherein X is any nucleotide with the proviso that at least 2 to 10 nucleotides are G and/or C nucleotides and the G/C content is at least 50 %, N is any nucleotide and a is selected such that the ribonucleic acid (or double-stranded segment thereof) has a length of at least 45 bp wherein the sequence of N is preferably heteropolymeric, and wherein the other strand of the ribonucleic acid or the double-stranded segment of the ribonucleic acid has a complementary sequence to the above defined sequence.
  • X is any nucleotide with the proviso that at least 2 to 10 nucleotides are G and/or C nucleotides and the G/C content is at least 50 %
  • N is
  • the ribonucleic acid of the present invention is completely double- stranded.
  • it is essentially double-stranded, i.e. there is regular hydrogen bonding between the opposite bases of the strands forming the double-stranded structure, but there may be one or several mismatches through non-complementary bases or through chemical modifications.
  • mismatches do not exceed 10%, more preferably 5 %, particularly preferred 2% or even 1 % of the double-stranded molecule (or double-stranded segment of the inventive RNA, respectively).
  • the ribonucleic acid of the invention containing the double-stranded structure may also have overhangs at one or both ends of the double- stranded structure which can be of various length but typically do not exceed ten single- stranded residues, more preferably such overhangs comprise one, two or three residues.
  • These overhangs may also comprise deoxyribonucleotides instead of ribonucleotides, if the overhang does not represent the 5' end containing the free triphosphate group.
  • the ribonucleic acid of the present invention containing a double-stranded structure may be composed of one polyribonucleic strand that has a sequence allowing the formation of a hairpin structure such that the double-stranded structure as defined before builds up under appropriate conditions.
  • the ribonucleic acid according to the present invention comprises two separate polyribonucleotide strands.
  • the strands of the at least one segment of double-stranded structure are selected from the following sequence pairs: ppp-5'- (G/C) x (N) y (G/C) z -3'
  • G/C is a G or C ribonucleotide with the proviso that when a G ribonucleotide is in a position in one strand the other strand has a C ribonucleotide in the opposite position and vice versa;
  • N is any ribonucleotide with the proviso that the sequences of both strands are essentially complementary;
  • each x is an integer of from 2 to 10, in particular 2, 3, 4, 5, 6, 7, 8, 9, or 10
  • each y is typically an integer of 30 to 200 or more such as 500 or 600, preferably, 30 to 150, more preferably 30 to 100, even more preferred 30 to 50, and each z is an integer of from 2 to 10, in particular 2, 3, 4, 5, 6, 7, 8, 9, or 10, with the proviso that x in one strand is equal to the x in the other strand, y in one strand is equal to the y in the other strand, and z in one strand is equal to the z in the other strand; and
  • the strands of the at least one segment of double-stranded structure are one of the following sequence pairs: ppp-5'- (G) 5 (N) y (G) 5 -3' 3'- (C) 5 (N) y (C) 5 -5' or ppp-5'- (C) 5 (N) y (C) 5 -3'
  • y is typically an integer of from 35 to 200 or more such as 500 or 600, preferably 35 to 150, more preferably 35 to 100, particularly preferred 35 to 80, even more preferred 35 to 40, and ppp denotes a free triphosphate group.
  • sequence of the double-stranded region between the G/C "clamps" of the ribonucleic acid of the invention is in principle not critical, however, homopolymers of any of the ribonucleobases A, U, G, or C, in particular G or C, are not well accepted due to their potential toxicity.
  • the sequence is chosen such that the overall sequence shows no evident complementarities to other existing RNA or DNA species in a cell or organism, particularly in order to avoid potential side effects from posttranscriptional gene silencing mechanisms.
  • the sequence between the C/C base pairs at both ends, or generally speaking, between the G/C clamps as defined above may be assembled from naturally occurring (partial) sequences that may be repeated.
  • An example is a certain (partial) sequence of, e.g.20 to 90 nucleotides, of a naturally occurring sequence, e.g. of a virus, microorganism or other organism, that is repeated once or several times such as two, three, four or five or even more times, in order to provide a molecule of the present invention having the appropriate or desired, respectively, length.
  • the double- stranded region between the G/C clamps is free of homopolymeric stretches of more than 5 contiguous identical nucleotides, and is free of short repeated sequence motifs of 3 to 10 nucleotides per motif.
  • the G/C content of the double-stranded structure (comprising the G/C clamps) is at least 45%, more preferably 45 to 70%, particularly preferred 48 to 60%. It is also contemplated that the sequence between the "clamps" contains further (short) stretches of G/C base pairs, e.g.3, 4 or 5 G/C base pairs.
  • Such embodiments of the invention usually have a Tm of the double-stranded structure of from 68 to 80 C.
  • preferred lengths of the dsRNA structure range from 45 to 150 bp, particularly preferred from 45 to 100 bp, even more preferred from 45 to 50 bp, i.e.45, 46, 47, 48, 49, or 50 bp.
  • Specific preferred examples of the double-stranded RNA according to the invention are composed of the following (complementary) sequence pairs (both strands are given in 5' to 3' direction from left to right; ppp denotes a free triphosphate group):
  • AAGCUCAGCAGCUAAGCCACGAGCUCAUGCGCCCCC-3 ' (SEQ ID NO: 7)
  • the RNA of the present invention may have overhangs on one or both sides, but it is typically blunt-ended on both sides of the double-stranded structure. It is contemplated that the RNA of the present invention is equipped with further entities to improve the immunostimulative properties. For example, it would be possible to include CpG deoxyribonucleotide motifs into the ribonucleic acid of the invention (one or more of them) in order to trigger the Toll-like receptor 9 (TRL-9), at least partially.
  • the RNA of the present invention may also contain one or more modified nucleotide analogues, in particular under stability considerations.
  • the chemical modification of the nucleotide analogue in comparison to the natural occurring nucleotide may be at the ribose, phosphate, and/or base moiety.
  • modifications at the backbone, i. e. the ribose and/or phosphate moieties are especially preferred.
  • ribose-modified ribonucleotides are analogues wherein the 2'-OH group is replaced by a group selected from H, OR, R, halo, SH, SR, NH 2 , NHR, NR 2 , or CN with R being C 1 -C 6 alkyl, alkenyl or alkynyl and halo being F, CI, Br or I.
  • modified ribonucleotide also includes 2'- deoxyderivatives, such as 2'-0-methyl derivatives, which may at several instances also be termed "deoxynucleotides”.
  • the at least one modified ribonucleotide may be selected from analogues having a chemical modification at the base moiety.
  • analogues include, but are not limited to, 5-aminoallyl-uridine, 6-aza-uridine, 8-aza-adenosine, 5-bromo- uridine, 7-deaza-adenine, 7-deaza-guanine, N 6 -methyl-adenine, 5-methyl-cytidine, pseudo- uridine, and 4-thio-uridine.
  • Examples of backbone-modified ribonucleotides wherein the phosphoester group between adjacent ribonucleotides is modified are phosphothioate groups.
  • the present invention also provides a method of producing the RNA as defined herein comprising the steps of: (i) synthesizing a ribonucleic acid having a sequence that folds into a form such that it adopts the double-stranded structure as defined above wherein a free triphosphate group is introduced at the 5'-end of the ribonucleic acid; or
  • polynucleotide molecules for providing the double-stranded RNA of the present invention may be prepared by chemical synthesis methods or enzymatically, or by a combination of chemical and enzymatic steps.
  • Methods for the enzymatic preparation of the double- stranded RNA molecules of the present invention are preferably those that use RNA- dependent RNA polymerases of caliciviruses as disclosed in WO-A-2007/012329. With respect to enzymatic synthesis of chemically modified dsRNAs using RNA-dependent RNA polymerases the methods referred to in WO 2009/150156 are preferred. Chemical synthesis methods for preparing RNA strands are also well-known in the art.
  • the present invention also contemplates a vector encoding RNA species as defined herein.
  • a single-stranded dsRNA-containing entity as disclosed herein may be expressed in the form of a shRNA derivative.
  • double-stranded RNAs of the invention can also be labelled (for example, if there is an overhang on one side of the double-strand structure) for detection in research or diagnostic applications.
  • the "label” can be any chemical entity which enables the detection of the RNA in question via physical, chemical, and all biological means. Examples of typical labels linked to or integrated into one or more of the nucleotides or added to one end of the molecules as disclosed herein are radioactive labels, chromophores, and fluorophores (e. g. fluorescein, TAM etc.).
  • the ribonucleic acids of the present invention are particularly for use as agonists of TLR-3 and/or RIG-I.
  • the RNA molecules of the present invention exert an immunostimulatory effect in cells or organisms.
  • Ribonucleic acids of the present invention are therefore useful as medicaments, in particular immunostimulatory preparations.
  • Ribonucleic acids of the present invention are also contemplated for the manufacture of a medicament for immunostimulation.
  • the present invention is therefore also directed to a pharmaceutical composition comprising at least one ribonucleic acid as defined herein in combination with at least one pharmaceutically acceptable carrier, excipient, and/or diluent.
  • a pharmaceutical composition comprising at least one ribonucleic acid as defined herein in combination with at least one pharmaceutically acceptable carrier, excipient, and/or diluent.
  • the preparation of pharmaceutical compositions in the context of the present invention, their dosages and their routes of administration are known to the skilled person, and guidance can be found in the latest edition of Remington's Pharmaceutical Sciences (Mack publishing Co., Eastern, PA, USA). It is also contemplated that the pharmaceutical compositions of the invention contain two or more different RNAs as defined herein.
  • RNA of the invention is used as an immunostimulatory drug alone, a topical administration of the appropriate preparation (e.g. a spray) to skin and/or mucosa is preferred.
  • a topical administration of the appropriate preparation e.g. a spray
  • the RNA of the present invention leads to stimulation of dendritic cells and generation of a CD8+ T cell response.
  • Such application of the inventive dsRNA is especially useful in the treatment of infectious diseases, e.g. by viruses (such as Herpesvirus, Papillomavirus) or in the treatment of cancer.
  • viruses such as Herpesvirus, Papillomavirus
  • the improved immunostimulatory effects the ribonucleic acids of the present invention are also useful in combination with a vaccine directed to a certain disease.
  • RNA of the invention may also be used as an "RNA adjuvant" in vaccine preparations (or administered in a distinct preparation together with the vaccine, or sequentially). Simultaneous or sequential administration of the vaccine and the immunostimulatory RNA of the present invention should improve the immune response against the antigen of the vaccine by generating a protective CD8+ T cell response to soluble proteins (antigens), triggering DC activation and induction of type I IFN production.
  • ribonucleic acids or pharmaceutical compositions as disclosed herein can also be combined with further immunostimulatory drugs known in the art.
  • the ribonucleic acids of the present invention are particularly useful in the treatment of diseases, including infectious diseases caused by infectious agents such as a bacterium, virus, and fungus, and tumours.
  • the present invention also provides a method for the treatment of a disease as mentioned above, preferably a viral infection or a tumour disease, comprising administering an effective amount of the pharmaceutical composition of the invention to a preferably mammalian, particularly human, patient in need of such treatment.
  • a disease as mentioned above, preferably a viral infection or a tumour disease
  • the present invention also relates to a cell or non-human organism being transfected or transformed with the double-stranded RNA molecule as defined herein or with a vector coding therefor.
  • the figures show:
  • Fig. 1 shows the sequences of the strands of double-stranded RNA molecules with a triphosphate moiety at one 5' end according to the invention called Riboxxim®-48 and Riboxxim®-90; length (in base pairs), Tm, G/C content and the presence of the triphosphate moiety are indicated.
  • Fig. 2 shows a photograph of an ethidium bromide-stained 10% polyacrylamide gel after electrophoretic separation of the indicated nucleic acids demonstrating their length.
  • An RNA marker corresponding to dsRNA of 100 bp is shown in the first lane from the left, and an RNA marker corresponding to dsRNA of 25 bp, 21 bp and 17 bp is shown in the fourth lane from the left.
  • RNAs according to the invention Riboxxim®-90 and Riboxxim® 48 are shown in the second and third lane, respectively, from the left.
  • Fig. 3 shows two diagrams indicating the concentration of the cytokine IL-6 in the cell culture supernatant of dendritic cells (slanDC, CD1 c+) and monocytes due to secretion of the cytokine by the indicated cells after stimulation with double-stranded RNA according to the invention bearing a triphosphate moiety, Riboxxim®-48 (Fig. 3A) or Riboxxim®-90 (Fig. 3B).
  • Fig. 4 shows diagrams of the concentration of IL-1 ⁇ in the cell culture supernatant of slan dendritic cells (Fig. 4A), myeloid dendritic cells (CD1 c+, Fig. 4B) and monocytes (Fig. 4C) indicating a dose-dependent secretion of I L-1 ⁇ after stimulation with Riboxxim®-90 in contrast to a dose-independent, generally high secretion of I L-1 ⁇ after stimulation with poly(l:C).
  • the cells were stimulated with 6.25 ⁇ g ml, 12.5 ⁇ g ml, 25 ⁇ g ml, and 50 ⁇ g ml of the respective nucleic acid.
  • Fig. 5 shows diagrams of the concentration of IL-6 in the cell culture supernatant of slan dendritic cells (Fig. 5A), myeloid dendritic cells (CD1 c+, Fig. 5B) and monocytes (Fig. 5C) indicating a dose-dependent secretion of IL-6 after stimulation with Riboxxim®-90 in comparison to the secretion of IL-6 after stimulation with poly(l:C).
  • the cells were stimulated with 6.25 ⁇ g ml, 12.5 ⁇ g ml, 25 ⁇ g ml, and 50 ⁇ g ml of the respective nucleic acid.
  • Fig. 6 shows diagrams of the concentration of I L 1 ⁇ (Fig. 6A) and IL-6 (Fig.
  • Fig. 7 shows the results of an electrospray ionization mass spectrometry of a double- stranded RNA-molecule bearing a triphosphate moiety at one 5' end, Riboxxim®-48;
  • the MS-analysis of the antisense strand, shown in Figure 7A, corresponds to the calculated mass of the strand with the following sequence:
  • Example 1 Secretion of IL-6 after stimulation with double-stranded RNA molecule having a triphosphate moiety at one 5' end
  • Isolated cells were grown in RPMI 1640 medium containing 10% human AB serum (CCPRO, Neustadt, Germany), 2 mM L-glutamine, 1 % nonessential amino acids, 100 U/ml penicillin, and 100 mg/ml streptomycin (Biochrom AG, Berlin, Germany). Cells were then seeded in 96- well plates at a density of 25,000 cells/well in RPMI-1640 with 10% human AB serum.
  • Subpopulations of dendritic cells or monocytes were stimulated with 50 ⁇ g/ml Riboxxim®-48 or Riboxxim®-90 for 24 to 72 hours.
  • the concentration of secreted IL-6 in the culture supernatant was assessed using ELISA.
  • Figure 3 shows the concentration of secreted IL-6 in the cell culture supernatant of dendritic cells and monocytes after incubation with Riboxxim®-48 (Fig. 3A) and Riboxxim-90 (Fig. 3B), respectively. Both nucleic acids strongly stimulate the secretion of IL-6 in all cell types. The data shown correspond to the mean values of three independent experiments with the respective standard error of the mean.
  • Example 2 Secretion of IL-1 ⁇ after stimulation with double-stranded RNA with a triphosphate moiety at one 5' end is dose-dependent
  • Dendritic cells slan DC and CD1 c+
  • monocytes were isolated, sorted and grown as described in example 1.
  • Cells were then seeded in 96-well plates at a density of 25,000 cells/well in RPMI-1640 with 10% human AB serum and incubated with 6.25 ⁇ / ⁇ , 12.5 ⁇ g ml, 25 ⁇ g ml, or 50 ⁇ g ml Riboxxim®-90 or poly(l:C) for 24 to 72 hours.
  • the concentration of secreted I L-1 ⁇ in the culture supernatant was assessed using ELISA.
  • Figure 4 shows the concentration of I L-1 ⁇ secreted by slanDC (Fig. 4A), CD1 c+ (Fig. 4B) and monocytes (Fig. 4C) after stimulation with increasing amounts of Riboxxim®-90 or poly(l:C). It is demonstrated that the secretion of I L-1 ⁇ in response to Riboxxim®-90 is dose- dependent in all three cell types, whereas poly(l:C) triggers a dose-independent and generally high secretion of I L-1 ⁇ , in particular in dendritic cells. The data shown correspond to the mean values of three independent experiments with the respective standard error of the mean.
  • Example 3 Secretion of IL-6 after stimulation with double-stranded RNA according to the invention bearing a triphosphate moiety at one 5' end is dose-dependent Dendritic cells (slan DC and CD1 c+) and monocytes were isolated, sorted and grown as described in example 1. Cells were then seeded in 96-well plates at a density of 25,000 cells/well in RPMI-1640 with 10% human AB serum and incubated with 6.25 ⁇ g ml, 12.5 ⁇ g ml, 25 ⁇ g ml, or 50 ⁇ g ml Riboxxim®-90 or poly(l:C) for 24 to 72 hours. The concentration of secreted IL-6 in the culture supernatant was assessed using ELISA.
  • Figure 5 shows the concentration of IL-6 secreted by slanDC (Fig. 5A), CD1 c+ (Fig. 5B) and monocytes (Fig. 5C) after stimulation with increasing amounts of Riboxxim®-90 or poly(l:C). It is demonstrated that the secretion of IL-6 in response to Riboxxim®-90 is dose-dependent in all three cell types, whereas poly(l:C) triggers a dose-independent and generally high secretion of IL-6, in particular in dendritic cells. The data shown correspond to the mean values of three independent experiments with the respective standard error of the mean.
  • Example 4 Comparison of IL-1 and IL-6 secretion after stimulation with double- stranded RNA according to the invention bearing a triphosphate moiety at one 5' -end with stimulation by not triphosphated dsRNA and poly(l:C)
  • Monocytes from two different healthy donors were isolated, sorted and grown as described in example 1. Cells were then seeded in 96-well plates at a density of 25,000 cells/well in RPMI-1640 with 10% human AB serum and incubated with 6,25 g/ml, 12,5 g/ml, 25 ⁇ glm ⁇ or 50 ⁇ g ml dsRNA-90, Riboxxim®-90 or poly(l:C), respectively, for 24 to 72 hours. The concentrations of secreted of I L-1 ⁇ and IL-6 in the culture supernatant were assessed using ELISA. The results are shown in Fig. 6A ( IL-1 ⁇ ) and Fig. 6B.
  • Triphosphated dsRNA of the invention (Riboxxim®-90) triggers a dose-dependent secretion of IL-1 ⁇ and IL-6.
  • the stimulation is higher than the stimulation exerted by not triphosphated dsRNA or by poly(l:C).
  • RNA-molecules according to the invention trigger the secretion of cytokines such as IL-6 and IL-1 ⁇ in dendritic cells and monocytes.
  • dsRNA of the invention containing a free 5'-triphosphate group results in a strictly dose-dependent cytokine secretion which is stronger than the cytokine secretion stimulated by not triphosphated dsRNA or by poly(l:C).
  • the capability of triggering a dose- dependent immune-response makes the double-stranded RNA-molecules according to the invention highly suitable to be utilized as RNA drugs for immunostimulation or adjuvants.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un ARN bicaténaire immunostimulateur d'au moins 45 paires de bases ou un ARN ayant au moins un segment bicaténaire d'au moins 45 paires de bases, respectivement, l'ARN contenant un groupe triphosphate libre à l'extrémité 5' d'au moins un brin.
PCT/EP2012/071641 2011-12-30 2012-10-31 Arn bicaténaire contenant un triphosphate pour l'immunostimulation Ceased WO2013097965A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161581994P 2011-12-30 2011-12-30
EP11196180 2011-12-30
US61/581,994 2011-12-30
EP11196180.1 2011-12-30

Publications (1)

Publication Number Publication Date
WO2013097965A1 true WO2013097965A1 (fr) 2013-07-04

Family

ID=48696360

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/071641 Ceased WO2013097965A1 (fr) 2011-12-30 2012-10-31 Arn bicaténaire contenant un triphosphate pour l'immunostimulation

Country Status (1)

Country Link
WO (1) WO2013097965A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015144736A1 (fr) * 2014-03-24 2015-10-01 Riboxx Gmbh Arns double brin conjugués et leur utilisation
KR20170057105A (ko) * 2015-11-13 2017-05-24 기초과학연구원 5' 말단의 인산기가 제거된 rna를 포함하는 리보핵산단백질 전달용 조성물
US10907161B2 (en) 2018-04-19 2021-02-02 Checkmate Pharmaceuticals, Inc. Synthetic RIG-I-like receptor agonists
WO2022189861A1 (fr) 2021-03-08 2022-09-15 Tollys Conjugués d'hydrates de carbone de ligands tlr3 et leurs utilisations

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007012329A2 (fr) 2005-07-25 2007-02-01 Technische Universität Dresden Arn polymerase dependant de l'arn, procedes et kits pour marquer et/ou amplifier l'arn
WO2008014979A2 (fr) * 2006-07-31 2008-02-07 Curevac Gmbh Acide nucléique de formule (i): gixmgn, ou(ii): cixmcn, en particulier en tant qu'agent/adjuvant immunostimulant
WO2008017473A2 (fr) 2006-08-08 2008-02-14 Gunther Hartmann Structure et utilisation d'oligonucléotides 5'-phosphate
EP2123757A1 (fr) * 2008-05-21 2009-11-25 Gunther Hartmann Oligonucléotides de triphosphate 5 avec extrémité franche et utilisations associées
WO2009150156A1 (fr) 2008-06-13 2009-12-17 Riboxx Gmbh Procédé permettant la synthèse enzymatique de l'arn modifié chimiquement
WO2010097414A1 (fr) * 2009-02-24 2010-09-02 Riboxx Gmbh Conception améliorée de petits arn interférants

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007012329A2 (fr) 2005-07-25 2007-02-01 Technische Universität Dresden Arn polymerase dependant de l'arn, procedes et kits pour marquer et/ou amplifier l'arn
WO2008014979A2 (fr) * 2006-07-31 2008-02-07 Curevac Gmbh Acide nucléique de formule (i): gixmgn, ou(ii): cixmcn, en particulier en tant qu'agent/adjuvant immunostimulant
WO2008017473A2 (fr) 2006-08-08 2008-02-14 Gunther Hartmann Structure et utilisation d'oligonucléotides 5'-phosphate
EP2123757A1 (fr) * 2008-05-21 2009-11-25 Gunther Hartmann Oligonucléotides de triphosphate 5 avec extrémité franche et utilisations associées
WO2009150156A1 (fr) 2008-06-13 2009-12-17 Riboxx Gmbh Procédé permettant la synthèse enzymatique de l'arn modifié chimiquement
WO2010097414A1 (fr) * 2009-02-24 2010-09-02 Riboxx Gmbh Conception améliorée de petits arn interférants

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", MACK PUBLISHING CO.
COFFMANN ET AL., IMMUNITY, 2010
FLORIAN EBERLE: "Activation of Innate Immunity by Ribonucleic Acids", HEIDELBERG, 7 April 2009 (2009-04-07), Heidelberg, pages 1 - 111, XP055053489, Retrieved from the Internet <URL:http://archiv.ub.uni-heidelberg.de/volltextserver/9414/1/Doktorarbeit_Finale.pdf> [retrieved on 20130214] *
FLORIAN EBERLE: "Activation of innate immunity by ribonucleic acids", HEIDELBERG, 7 April 2009 (2009-04-07), Heidelberg, pages 1 - 3, XP055053488, Retrieved from the Internet <URL:http://archiv.ub.uni-heidelberg.de/volltextserver/9414/1/Doktorarbeit_Finale.pdf> [retrieved on 20130214] *
KUCNICK ET AL., CURRENT MEDICAL CHEMISTRY, 2010
SCHAEKEL, K. ET AL., EUR. J. IMMUNOL., vol. 28, 1998, pages 4084 - 4093

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015144736A1 (fr) * 2014-03-24 2015-10-01 Riboxx Gmbh Arns double brin conjugués et leur utilisation
US10273484B2 (en) 2014-03-24 2019-04-30 Riboxx Gmbh Double-stranded RNA conjugates and their use
KR20170057105A (ko) * 2015-11-13 2017-05-24 기초과학연구원 5' 말단의 인산기가 제거된 rna를 포함하는 리보핵산단백질 전달용 조성물
KR101885901B1 (ko) * 2015-11-13 2018-08-07 기초과학연구원 5' 말단의 인산기가 제거된 rna를 포함하는 리보핵산단백질 전달용 조성물
US10767174B2 (en) 2015-11-13 2020-09-08 Institute For Basic Science Method for RGEN RNP delivery using 5′-phosphate removed RNA
US10907161B2 (en) 2018-04-19 2021-02-02 Checkmate Pharmaceuticals, Inc. Synthetic RIG-I-like receptor agonists
US12123003B2 (en) 2018-04-19 2024-10-22 Checkmate Pharmaceuticals, Inc. Synthetic RIG-I-like receptor agonists
WO2022189861A1 (fr) 2021-03-08 2022-09-15 Tollys Conjugués d'hydrates de carbone de ligands tlr3 et leurs utilisations

Similar Documents

Publication Publication Date Title
EP2773760B2 (fr) Arn double brin pour l&#39;immunostimulation
JP7071299B2 (ja) ５’リン酸オリゴヌクレオチドの構造および使用
EP4015636B1 (fr) Oligonucléotide de triphosphate 5&#39; avec extrémité franche et utilisations associées
EA008741B1 (ru) Аналоги олигонуклеотидов с-класса с улучшенной иммуностимулирующей эффективностью
WO2013097965A1 (fr) Arn bicaténaire contenant un triphosphate pour l&#39;immunostimulation
EP1920775B1 (fr) Oligonucleotide 5&#39;triphosphate induisant une réaction antivirale
US20240035035A1 (en) Compositions and methods for treating, ameliorating, and/or preventing viral infections
WO2021038089A1 (fr) Arn messagers minimaux et leurs utilisations
CN111154755B (zh) 一种双链寡核苷酸dna及其应用
HK1225755B (en) 5&#39; triphosphate oligonucleotide with blunt end and uses thereof
HK1225755A1 (en) 5&#39;triphosphate oligonucleotides with blunt ends and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12778764

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12778764

Country of ref document: EP

Kind code of ref document: A1